Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Amifampridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amifampridine SCHEMBL29354458 | 1.00 | — | — | |
| Amifampridine SCHEMBL8907371 | 0.97 | GAA (0.56) | — | |
| Amifampridine SCHEMBL30609183 | 0.97 | — | — | |
| Amifampridine SCHEMBL28271256 | 0.97 | — | — | |
| Amifampridine SCHEMBL11016903 | 0.97 | — | — | |
| Amifampridine SCHEMBL8907368 | 0.97 | GAA (0.56) | — | |
| Amifampridine SCHEMBL19410631 | 0.97 | GAA (0.56) | — | |
| Amifampridine SCHEMBL28271266 | 0.94 | GAA (0.54) | — | |
| Amifampridine SCHEMBL27516080 | 0.92 | GAA (0.52) | — | |
| Amifampridine SCHEMBL5308533 | 0.89 | ALDH1A1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8405 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2026-02-12 | — | — | US | claimed |
| EP-4665351-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | University of Rochester (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025237878-A1 | LOW BLEEDING PERYLENE BLACK PIGMENTS AND PROCESS FOR PRODUCING THE SAME | SUN CHEMICAL B.V. (NL) | 2025-11-20 | — | — | WO | claimed |
| US-20250345458-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL INC (US) | 2025-11-13 | — | — | US | claimed |
| EP-4181907-B1 | TREATMENT OF CONGENITAL MYASTHENIC SYNDROME USING DOK7 GENE OR POLYPEPTIDE | UNIV OXFORD INNOVATION LTD (GB) | 2025-09-03 | — | — | EP | claimed |
| EP-3622079-B1 | COMPOSITIONS FOR FACILITATING MEMBRANE FUSION AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| CN-119843383-B | Micro-copolymerization modified polyamide 66 fiber and preparation method thereof | 浙江理工大学 | 2025-06-17 | — | — | CN | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-118782152-B | Organic heterocyclic biomarker for wild and cultivated four-large family fish population and application thereof | 中国水产科学研究院长江水产研究所 | 2025-05-20 | — | — | CN | claimed |
| EP-0196224-B1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1989-08-16 | — | — | EP | claimed |
| US-4855290-A | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1989-08-08 | — | — | US | claimed |
| EP-0314444-A2 | Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-05-03 | — | — | EP | claimed |
| EP-0303391-A2 | Optical isomers of a spiroquinuclidine derivative | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-02-15 | — | — | EP | claimed |
| EP-0095278-B1 | 5-OXO-2-PYRROLIDINEPROPANOIC ACID DERIVATIVES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-30 | — | — | EP | claimed |
| US-4753722-A | OXIDATION TO DISULFIDES | MERICHEM COMPANY (US) | 1988-06-28 | — | — | US | claimed |
| EP-0205247-A2 | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1986-12-17 | — | — | EP | claimed |
| EP-0196224-A1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1986-10-01 | — | — | EP | claimed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | claimed |
| US-4386095-A | NERVOUS SYSTEM DISORDERS; AGING | CORNELL RESEARCH FOUNDATION, INC. (US) | 1983-05-31 | — | — | US | claimed |